Enzychem Lifesciences Corporation (KOSDAQ:183490)
South Korea · Delayed Price · Currency is KRW 1,017.00
-8.00 (-0.78%)
Aug 8, 2025, 3:30 PM KST
Enzychem Lifesciences Company Description
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea.
It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19.
The company was founded in 1999 and is headquartered in Seoul, South Korea.
Enzychem Lifesciences Corporation
| Country | South Korea |
| Founded | 1999 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Ki-Young Sohn |
Contact Details
Address: aT Center Seoul South Korea | |
| Phone | 82 2 501 1084 |
| Website | enzychem.com |
Stock Details
| Ticker Symbol | 183490 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7183490002 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ki-Young Sohn | Chief Executive Officer |